The clinical study of weekly docetaxel combined with cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer

( views:594, downloads:0 )
Author:
HUO Wei(Department of Medical oncology, Dalian Central Hospital, Dalian 116030, China)
LI Zhi-min(Department of Medical oncology, Dalian Central Hospital, Dalian 116030, China)
ZHU Xiao-min(Department of Medical oncology, Dalian Central Hospital, Dalian 116030, China)
()
Journal Title:
CHINA CLINICAL PRACTICAL MEDICINE
Issue:
Volume 04, Issue 12, 2010
DOI:
10.3760/cma.j.issn 1673-8799.2010.12.49
Key Word:
Advanced gastric cancer(AGC);Docetaxel(TXT);Cisplatin(DDP)

Abstract: Objective To evaluate the efficacy and toxicity of docetaxel(TXT) plus cisplatin(DDP) for patients with metastatic or recurrent advanced gastric cancer(AGC), previously treated with FOLFOX4 or XELOX regimen. Methods Twenty-seyen patients were treated with docetaxel (35 mg/m2 on day 1 and 8)and cisplatin (20 mg/m2 on days 1 to 5) every 3 weeks. Results Of the 36 patients qualified for efficacy analysis,the overall response rate was 27. 8% , including 10 cases of PR, 12 cases of SD and 14 cases of PD respectively. The median time to progression was 4. 4 months and median survival time was 6. 5 months. The predominant toxicity was hematologic, with neutrop enia. Non-hematological toxicity was rarely severe. Conclusion Combination chemotherapy with TXT/DDP given on 2 out of 3 weeks is well tolerated and active in heavily pretreated patients with AGC, even after prior exposure to OXA and 5-FU.

  • [1]Sasaki T,Maeda Y,kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Gan To Kagaku Ryoho,2000,27(2):166-176.
  • [2]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55(2):74-108.
  • [3]金懋林,陈强,程凤歧,等.奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌的研究.中华肿瘤杂志,2003,25(2):172-174.
  • [4]Cavanna L,Artioli F,Codignola C,et al.Oxaliplatin in combination with 5-fluorouracil(5-FU)and leucovorin(LV) in patients with metastatic gastric cancer (MGC).Am J Clin Oncol,2006,29(4):371-375.
  • [5]Fulton B,Spencer CM.Docetaxel.A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.Drugs,1996,51 (6),1075-1092.
  • [6]Ferlini C,Scambia G,Distefano M,et al.Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptornegative cancer cell lines is mediated by the induction of apoptosis.Br J Cancer,1997,75(6),884-891.
  • [7]Bang YJ,Kang WK,Kang YK,et al.Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:a phase Ⅱ trial,2002,32(7),248-254.
  • [8]Mavroundis D,Kourousis C,Androu lakis N,et al.Frontlinc treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor(G-CSF):a phase Ⅱ trail(group B).Am J Clin Oncomn,2000,23(4):341-344.
  • [9]Giuliani F,Gebbia V,De Vita F,et al.Docetaxel as salvage therapy in advanced gastric cancer:a phase Ⅱ study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.).Anticancer Res,2003,23 (5b):4219-4222.
  • [10]Maeda S,Sugiura T,Saikawa Y,et al.Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.Cancer Sci,2004,95 (8):679-684.
  • [11]Park SH,Kang WK,Lee HR,et al.Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.Am J Clin Oncol,2004,27(5):477-480.
  • [12]Kim H,Park JH,Bang SJ,et al.A phase Ⅱ study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.Jpn J Clin Oncol,2005,35 (12):727-732.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn